Abstract | OBJECTIVE: METHODS: Patients with a total score of 9-23 in the Syndrom-Kurz test (SKT) cognitive test battery (cognitive domain) and with a composite score 6 and greater in the Neuropsychiatric Inventory (NPI; behavioural domain) were included. Three trials compared 2 × 120 mg/day or 1 × 240 mg/day EGb 761(®) to placebo while one used donepezil as an active control. The duration of randomised treatment was 22 or 24 weeks. RESULTS: One thousand, two hundred and ninety-four patients were analysed for efficacy. Patients treated with EGb 761(®) showed improvements of cognitive performance and behavioural symptoms that were associated with advances in activities of daily living and a reduced burden to caregivers. Placebo-treated patients, on the other hand, showed only minimal improvements or signs of progression. In each placebo-controlled trial, EGb 761(®) was significantly superior in all mentioned domains (p < 0.01). In the actively controlled trial, EGb 761(®) and donezepil as well as a combination of both drugs had similar effects. CONCLUSIONS: The review supports the efficacy of EGb 761(®) in age-related dementia with neuropsychiatric features. The drug was safe and well-tolerated.
|
Authors | Ralf Ihl |
Journal | International journal of psychiatry in clinical practice
(Int J Psychiatry Clin Pract)
Vol. 17 Suppl 1
Pg. 8-14
(Nov 2013)
ISSN: 1471-1788 [Electronic] England |
PMID | 23808613
(Publication Type: Journal Article, Review)
|
Chemical References |
- Neuroprotective Agents
- Placebos
- Plant Extracts
- Ginkgo biloba extract
|
Topics |
- Activities of Daily Living
- Dementia
(drug therapy, psychology)
- Ginkgo biloba
- Humans
- Multicenter Studies as Topic
- Neuroprotective Agents
(pharmacology, therapeutic use)
- Neuropsychological Tests
- Outcome Assessment, Health Care
(statistics & numerical data)
- Phytotherapy
- Placebos
- Plant Extracts
(pharmacology, therapeutic use)
- Randomized Controlled Trials as Topic
- Severity of Illness Index
|